# US 2021/0171435 A1 · Methods for the Treatment of Diabetic Retinopathy and other Ophthalmic Diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0171435 A1
- Document ID: US20210171435A1
- Status: Published application
- Kind: A1
- Application number: 16/934,715
- Filed: 2020-07-21
- Published: 2021-06-10
- Earliest claimed: 2012-05-04
- Assignees: Acucela Inc.
- Applicants: Acucela Inc.
- Inventors: Claes Olof BAVIK; Susan Hayes HENRY; Ryo KUBOTA; Vladimir A. KUKSA
- Web page: https://patentgrep.com/patent/US20210171435A1

## CPC

- C07C 215/08: with only one hydroxy group and one amino group bound to the carbon skeleton
- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K 31/138: Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine (atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377)
- A61K 31/35: having six-membered rings with one oxygen as the only ring hetero atom
- A61K 31/765: Polymers containing oxygen
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 27/02: Ophthalmic agents
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 27/10: for accommodation disorders, e.g. myopia
- A61P 39/00: General protective or antinoxious agents
- C07C 211/27: having amino groups linked to the six-membered aromatic ring by saturated carbon chains
- C07C 217/20: by halogen atoms, by trihalomethyl, nitro or nitroso groups, or by singly-bound oxygen atoms
- C07C 323/32: having at least one of the nitrogen atoms bound to an acyclic carbon atom of the carbon skeleton
- C07D 309/06: Radicals substituted by oxygen atoms
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Methods are provided herein for the treatment of ophthalmic diseases or conditions such as an ophthalmic disease or disorder associated with diabetes in a patient. Also provided herein are methods of treating retinopathy of prematurity in a patient. Further, provided herein are methods for treating wet age-related macular degeneration in a patient. The methods comprise administration of compounds disclosed herein to a patient in need thereof that inhibit or slow one or more signs or symptoms of such conditions.

## Claims

### Claim 1

(canceled)

### Claim 2

A method for treating an ophthalmic disease or disorder associated with neovascularization in the eye of a patient comprising administering a therapeutically effective amount of a composition comprising a compound of Formula (A), or tautomer, stereoisomer, geometric isomer, N-oxide or a pharmaceutically acceptable salt thereof:
wherein,
X is selected from —C(R9)═C(R9)—, —C(R9)2—O—, —C(R9)2—C(R9)2—, —C(R9)2—S—, —C(R9)2—S(O)2—, or —C(R9)2—NR9—;
Y is selected from:
a) substituted or unsubstituted carbocyclyl, optionally substituted with C1-C4 alkyl, halogen, —OH, or C1-C4 alkoxy;
b) substituted or unsubstituted carbocyclylalkyl, optionally substituted with C1-C4 alkyl, halogen, —OH, or C1-C4 alkoxy;
c) substituted or unsubstituted aralkyl, optionally substituted with C1-C4 alkyl, halogen, —OH, or C1-C4 alkoxy; or
d) substituted or unsubstituted C3-C10 alkyl, optionally substituted with halogen, —OH, or C1-C4 alkoxy;
R1 is hydrogen and R2 is hydroxyl;
R7 is hydrogen;
R8 is hydrogen;
each R9 independently hydrogen, or substituted or unsubstituted C1-C4 alkyl;
each R33 is independently selected from halogen or substituted or unsubstituted C1-C4 alkyl, and n is 0, 1, 2, 3, or 4.

### Claim 3

(canceled)

### Claim 4 (depends on 2)

The method of claim 2, wherein
n is 0, 1, or 2.

### Claim 5

(canceled)

### Claim 6

(canceled)

### Claim 7 (depends on 4)

The method of claim 4, wherein
X is —C(R9)2—O—.

### Claim at position 8

-11. (canceled)

### Claim 12

(canceled)

### Claim 13 (depends on 12)

The method of claim 12, wherein Y is substituted or unsubstituted carbocyclyl.

### Claim 14

(canceled)

### Claim 15 (depends on 13)

The method of claim 13, wherein the substituted or unsubstituted carbocyclyl is a substituted or unsubstituted 4-, 5-, 6-, or 7-membered ring.

### Claim 16

(canceled)

### Claim 17

(canceled)

### Claim 18

(canceled)

### Claim 19 (depends on 15)

The method of claim 15, wherein the substituted or unsubstituted carbocyclyl is a 6-membered ring.

### Claim 20 (depends on 19)

The method of claim 19, wherein the substituted or unsubstituted 6-membered ring is a substituted or unsubstituted cyclohexyl.

### Claim 21

(canceled)

### Claim 22

(canceled)

### Claim 23

(canceled)

### Claim 24

(canceled)

### Claim at position 22

-35. (canceled)

### Claim 36 (depends on 2)

The method of claim 2, wherein the composition comprises a compound, or stereoisomer, N-oxide or a pharmaceutically acceptable salt thereof, having the structure:

### Claim at position 24

-42. (canceled)

### Claim 43 (depends on 36)

The method of claim 36, wherein the composition is administered to the patient orally.

### Claim 44

(canceled)

### Claim 45 (depends on 36)

The method of claim 36, wherein treatment results in improvement of central vision in the patient.

### Claim at position 28

-56. (canceled)

### Claim 47 (depends on 2)

The method of claim 2, wherein the ophthalmic disease or disorder associated with neovascularization is choroidal neovascularization.

### Claim 48 (depends on 2)

The method of claim 2, wherein the ophthalmic disease or disorder associated with neovascularization is selected from: defects in Bruch's membrane, increases in amount of ocular vascular endothelial growth factor (VEGF), myopia, myopic degeneration, deterioration of central vision, metamorphopsia, color disturbances, hemorrhaging of blood vessels, or a combination thereof.

### Claim 49 (depends on 2)

The method of claim 2, wherein the ophthalmic disease or disorder associated with neovascularization is retinal neovascularization.

### Claim 50 (depends on 2)

The method of claim 2 wherein the ophthalmic disease or disorder associated with neovascularization is wet age-related macular degeneration.

### Claim at position 33

-54. (canceled)

### Claim 55 (depends on 2)

The method of claim 2, wherein the ophthalmic disease or disorder associated with neovascularization is neovascular age-related macular degeneration.

### Claim 56 (depends on 2)

The method of claim 2, wherein the ophthalmic disease or disorder associated with neovascularization is selected from sickle cell retinopathy, Eales disease, ocular ischemic syndrome, carotid cavernous fistula, familial exudative vitreoretinopathy, hyperviscosity syndrome, idiopathic occlusive arteriolitis, radiation retinopathy, retinal vein occlusion, retinal artery occlusion, retinal embolism, birdshot retinochoroidopathy, retinal vasculitis, sarcoidosis, toxoplasmosis, uveitis, choroidal melanoma, chronic retinal detachment, incontinentia pigmenti, and retinitis pigmentosa.

### Claim 57 (depends on 36)

The method of claim 36, wherein the ophthalmic disease or disorder associated with neovascularization is choroidal neovascularization.

### Claim 58 (depends on 36)

The method of claim 36, wherein the ophthalmic disease or disorder associated with neovascularization is selected from: defects in Bruch's membrane, increases in amount of ocular vascular endothelial growth factor (VEGF), myopia, myopic degeneration, deterioration of central vision, metamorphopsia, color disturbances, hemorrhaging of blood vessels, or a combination thereof.

### Claim 59 (depends on 36)

The method of claim 36, wherein the ophthalmic disease or disorder associated with neovascularization is retinal neovascularization.

### Claim 60 (depends on 36)

The method of claim 36 wherein the ophthalmic disease or disorder associated with neovascularization is wet age-related macular degeneration.

### Claim 61 (depends on 36)

The method of claim 36, wherein the ophthalmic disease or disorder associated with neovascularization is neovascular age-related macular degeneration.

### Claim 62 (depends on 36)

The method of claim 36, wherein the ophthalmic disease or disorder associated with neovascularization is selected from sickle cell retinopathy, Eales disease, ocular ischemic syndrome, carotid cavernous fistula, familial exudative vitreoretinopathy, hyperviscosity syndrome, idiopathic occlusive arteriolitis, radiation retinopathy, retinal vein occlusion, retinal artery occlusion, retinal embolism, birdshot retinochoroidopathy, retinal vasculitis, sarcoidosis, toxoplasmosis, uveitis, choroidal melanoma, chronic retinal detachment, incontinentia pigmenti, and retinitis pigmentosa.

### Claim 63 (depends on 57)

The method of claim 57, wherein the method is further characterized by suppression of progression of the ophthalmic disease or disorder.

### Claim 64 (depends on 58)

The method of claim 58, wherein the method is further characterized by suppression of progression of the ophthalmic disease or disorder.

### Claim 65 (depends on 59)

The method of claim 59, wherein the method is further characterized by suppression of progression of the ophthalmic disease or disorder.

### Claim 66 (depends on 60)

The method of claim 60, wherein the method is further characterized by suppression of progression of the ophthalmic disease or disorder.

### Claim 67 (depends on 61)

The method of claim 61, wherein the method is further characterized by suppression of progression of the ophthalmic disease or disorder.

### Claim 68 (depends on 62)

The method of claim 62, wherein the method is further characterized by suppression of progression of the ophthalmic disease or disorder.

### Claim 69 (depends on 57)

The method of claim 57, wherein the compound is administered as a daily dose of about 2 mg; about 5 mg; about 7 mg; or about 10 mg.

### Claim 70 (depends on 58)

The method of claim 58, wherein the compound is administered as a daily dose of about 2 mg; about 5 mg; about 7 mg; or about 10 mg.

### Claim 71 (depends on 59)

The method of claim 59, wherein the compound is administered as a daily dose of about 2 mg; about 5 mg; about 7 mg; or about 10 mg.

### Claim 72 (depends on 60)

The method of claim 60, wherein the compound is administered as a daily dose of about 2 mg; about 5 mg; about 7 mg; or about 10 mg.

### Claim 73 (depends on 61)

The method of claim 61, wherein the compound is administered as a daily dose of about 2 mg; about 5 mg; about 7 mg; or about 10 mg.

### Claim 74 (depends on 62)

The method of claim 62, wherein the compound is administered as a daily dose of about 2 mg; about 5 mg; about 7 mg; or about 10 mg.
